دورية أكاديمية
Point-of-Care Diagnostic Assays and Novel Preclinical Technologies for Hemostasis and Thrombosis.
| العنوان: | Point-of-Care Diagnostic Assays and Novel Preclinical Technologies for Hemostasis and Thrombosis. |
|---|---|
| المؤلفون: | Caruso C; Department of Pediatrics, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia., Lam WA; Department of Pediatrics, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia.; Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine, Georgia Institute of Technology, Atlanta, Georgia. |
| المصدر: | Seminars in thrombosis and hemostasis [Semin Thromb Hemost] 2021 Mar; Vol. 47 (2), pp. 120-128. Date of Electronic Publication: 2021 Feb 26. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Thieme Country of Publication: United States NLM ID: 0431155 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-9064 (Electronic) Linking ISSN: 00946176 NLM ISO Abbreviation: Semin Thromb Hemost Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, NY : Thieme Original Publication: New York, Stratton Intercontinental Medical Book Corp. |
| مواضيع طبية MeSH: | Hemostasis/*immunology , Microfluidics/*methods , Point-of-Care Testing/*standards , Thrombosis/*immunology, Humans |
| مستخلص: | Hemostasis is a complex wound-healing process involving numerous mechanical and biochemical mechanisms and influenced by many factors including platelets, coagulation factors, and endothelial components. Slight alterations in these mechanisms can lead to either prothrombotic or bleeding consequences, and such hemostatic imbalances can lead to significant clinical consequences with resultant morbidity and mortality. An ideal hemostasis assay would not only address all the unique processes involved in clot formation and resolution but also take place under flow conditions to account for endothelial involvement. Global assays do exist; however, these assays are not flow based. Flow-based assays have been limited secondary to their large blood volume requirements and low throughput, limiting potential clinical applications. Microfluidic-based assays address the aforementioned limitations of both global and flow-based assays by utilizing standardized devices that require low blood volumes, offer reproducible analysis, and have functionality under a range of shear stresses and flow conditions. While still largely confined to the preclinical space, here we aim to discuss these novel technologies and potential clinical implications, particularly in comparison to the current, commercially available point-of-care assays. Competing Interests: W.A.L. reports grants from NIH, during the conduct of the study, and nonfinancial support from Sanguina, Inc, outside the submitted work. (Thieme. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20210226 Date Completed: 20210928 Latest Revision: 20210928 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1055/s-0041-1723798 |
| PMID: | 33636744 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-9064 |
|---|---|
| DOI: | 10.1055/s-0041-1723798 |